Clinical Trial

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label, multiple ascending dose investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CC312 in adult patients with relapsed or refractory autoimmune diseases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-22.
Trial Details
NCT Number NCT07193810
Lead Sponsor CytoCares Inc
Conditions SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies, SSc-Systemic Sclerosis
Enrollment 6 participants
Start Date 2025-09-23
Primary Completion 2027-09-29 (estimated)
Study Completion 2027-09-29 (estimated)
Updated on ClinicalTrials.gov 2026-04-14